Skip to content

Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

Evidence-based Assessment of Medication Sensitivity in Acute Hepatic Porphyria

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03906214
Enrollment
60
Registered
2019-04-08
Start date
2019-04-03
Completion date
2019-09-13
Last updated
2019-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Porphyrias

Keywords

Porphyrias, Variegate Porphyria, Hereditary Coproporphyria, Acute Intermittent Porphyria

Brief summary

This is an observational study collecting patient/caregiver reports on suspected medication/drug-induced acute porphyria attacks, as well as safe use of drugs previously labeled unsafe or with unknown risk. Participants will be recruited through the RDCRN Contact Registry for the Porphyrias Consortium. The study will be advertised on the Consortium website and through the American Porphyria Foundation's social media network.

Detailed description

Contact Registrants will be sent an email invitation describing the study. A unique link will be generated for each registrant and included in the email invitation. After 2 weeks, a second email invitation will be sent to the registrants who have not yet participated. After 1 month, a third email invitation will be sent to the registrants who have not yet participated. We may send additional emails periodically (e.g. every 6-12 months) to subjects enrolled to remind them to complete new surveys if they have taken any other medications of interest or have experienced any new reactions/attacks. If the registrant wants to participate in the study, he/she will follow the survey link in the email invitation, which directs him/her to an IRB-approved online consent form. If the participant consents to participate, he/she will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use.

Interventions

Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use.

Sponsors

University of Texas
CollaboratorOTHER
Wake Forest University Health Sciences
CollaboratorOTHER
University of Miami
CollaboratorOTHER
University of Washington
CollaboratorOTHER
Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
University of California, San Francisco
CollaboratorOTHER
University of Utah
CollaboratorOTHER
National Institutes of Health (NIH)
CollaboratorNIH
University of South Florida
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Able to read and write in English * Enrolled in the RDCRN PC Contact Registry * Self-reported patient or caregiver of patient with acute porphyria There are no restrictions on age, sex or ethnicity. However, the following criteria will be applied to those reports that are considered evaluable (analyzed and scored): 1. Medication name must be specified 2. The data elements required in the scoring system must be complete

Exclusion criteria

* Unable to provide informed consent and complete forms

Design outcomes

Primary

MeasureTime frameDescription
Acute Attack Form5 years from study startDesigned to capture PBG levels, characteristics of the acute attack, timing of medication administration, and pharmacological information on the medication.
Uneventful Use of Possible Risky Medication Form5 years from study startDesigned to capture details of medication in question, ALA/PGB results during use of medication in questions, concomitant medication use, diet history, and alcohol use.
Use of Medications of Interest Form5 years from study startDesigned to assess medications used by category and effects of each.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026